Researchers generate human antibodies in the lab

Image
IANS Bengaluru
Last Updated : Jul 25 2017 | 11:32 AM IST

A new laboratory technique that will accelerate development of vaccines to protect people from a wide range of diseases has been reported by an international team of scientists.

Normally, vaccines induce B-lymphocytes or B-cells of the body's immune system to produce antibodies that fight against invading pathogens like viruses.

In the new study, researchers have developed a method to rapidly produce specific human antibodies in the laboratory itself from B-cells isolated from patient blood samples and by replicating the same processes these cells use in the body to prevent infections.

The technique, reported in the Journal of Experimental Medicine, could potentially accelerate the development of new vaccines by allowing the efficient evaluation of candidate target antigens, it is claimed.

The researchers, from Francis Crick Institute in London and the Ragon Institute of Massachusetts General Hospital in the US, successfully demonstrated their approach using various bacterial and viral antigens and proteins from several strains of influenza A.

In each case, the researchers were able to produce specific high-affinity antibodies in just a few days and were also able to generate antibodies against HIV (which causes AIDS) from B-cells isolated from HIV-free patients.

The scientists believe their approach will help researchers generate therapeutic antibodies within a shorter time frame in the laboratory for the treatment of infectious diseases and other conditions such as cancer.

(K.S. Jayaraman is a senior journalist who writes on scientific issues. He can be contacted at killugudi@hotmail.com)

--IANS

ksj/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 25 2017 | 11:22 AM IST

Next Story